JAMES C YAO to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications JAMES C YAO has written about TOR Serine-Threonine Kinases.
Connection Strength
1.208
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
Score: 0.248
-
mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer. 2011 Jun; 18(3):C15-8.
Score: 0.233
-
Perspectives in the development of novel treatment approaches. Tumori. 2010 Sep-Oct; 96(5):858-73.
Score: 0.223
-
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013 Mar 01; 73(5):1449-53.
Score: 0.066
-
The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012 Nov 15; 72(22):5683-91.
Score: 0.064
-
New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res. 2012 Apr 01; 18(7):1830-6.
Score: 0.062
-
Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011 Mar; 30 Suppl 1:27-34.
Score: 0.058
-
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23.
Score: 0.057
-
Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park). 2008 Dec; 22(14):1617-23; discussion 1623-4, 1629.
Score: 0.049
-
Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am. 2007 Jun; 21(3):575-81; x.
Score: 0.044
-
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007 Mar; 21(1):163-72.
Score: 0.044
-
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na?ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90.
Score: 0.023
-
Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009 Mar 01; 15(5):1821-9.
Score: 0.013
-
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66.
Score: 0.012
-
Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008; 38(3):195-209.
Score: 0.012